# The Lancet Haematology

Source: https://onco.cc/journals/lancet-haematology/  
OnCo record `lancet-haematology` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Lancet Haematology is the Lancet's haematology journal, publishing phase 2 and 3 trials in leukaemia, lymphoma and myeloma, transplant studies and global-access commentary on blood cancers.

## Summary

The Lancet Haematology (Lancet Haematol) is the Lancet's haematology journal, appearing monthly since 2014 and published by Elsevier on a hybrid model. It publishes randomised and single-arm phase 2 and 3 trials in leukaemia, lymphoma and myeloma, including CAR-T and bispecific follow-up and MDS and myelofibrosis studies, together with transplant studies, long-term outcomes, Commissions on haematological care in low-income settings and global-access commentary on blood cancers. Its readers are haematologists and trialists who follow the clinical evidence in blood cancers. Within OnCo it is the journal of the phase 1/2 paper on talicabtagene autoleucel for relapsed or refractory B-cell malignancies, and it is where a reader would look for CAR-T and bispecific trial follow-up.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: Lancet Haematol
- Publisher: Elsevier
- Scope: haematology
- Access: hybrid

## Sources

- Lancet journals: https://www.thelancet.com

## Connected records

- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Randomised trial](https://onco.cc/terms/randomised-trial/), [Relapsed / refractory (R/R)](https://onco.cc/terms/relapsed-refractory/)
- people: [Elisabeth Schorb](https://onco.cc/people/elisabeth-schorb/), [Ruben Mesa](https://onco.cc/people/ruben-mesa/), [Valdas Pečeliūnas](https://onco.cc/people/valdas-peceliunas/)
- key papers: [A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial](https://onco.cc/key-papers/paper-cd19-multiple-myeloma-lancet-haematol-2019/), [EsPhALL2010: continuous imatinib with chemotherapy in paediatric Philadelphia chromosome-positive ALL](https://onco.cc/key-papers/paper-esphall2010-continuous-imatinib-biondi-lancet-haematol-2018/), [IELSG32 first randomisation: the MATRix regimen (methotrexate, cytarabine, thiotepa, rituximab) in primary CNS lymphoma](https://onco.cc/key-papers/paper-ielsg32-matrix-induction-ferreri-lancet-haematol-2016/), [IELSG32 second randomisation: whole-brain radiotherapy or autologous stem cell transplant as consolidation in primary CNS lymphoma](https://onco.cc/key-papers/paper-ielsg32-wbrt-vs-asct-consolidation-ferreri-lancet-haematol-2017/), [Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study](https://onco.cc/key-papers/paper-gisslinger-lancet-haematol/), [Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial](https://onco.cc/key-papers/paper-zeidan-lancet-haematol/), [Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study](https://onco.cc/key-papers/paper-jain-talicabtagene-lancet-haem-2025/), [Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial](https://onco.cc/key-papers/paper-zanubrutinib-cll-lancet-haematol-2021/)

---
JSON: https://onco.cc/api/v1/entities/lancet-haematology.json